Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours

NCT04810208 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic decision

Conditions

Solid Tumor

Interventions

DRUG: Docetaxel

Sponsor

Lidds AB